Financials data is unavailable for this security.
View more
Year on year United Laboratories International Holdings Ltd grew revenues 21.22% from 11.33bn to 13.74bn while net income improved 70.85% from 1.58bn to 2.70bn.
| Gross margin | 46.15% |
|---|---|
| Net profit margin | 20.75% |
| Operating margin | 26.32% |
| Return on assets | 13.65% |
|---|---|
| Return on equity | 23.21% |
| Return on investment | 20.72% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at United Laboratories International Holdings Ltd fell by 481.08m. However, the company earned 2.44bn from its operations for a Cash Flow Margin of 17.75%. In addition the company used 1.56bn on investing activities and also paid 1.36bn in financing cash flows.
| Cash flow per share | 2.07 |
|---|---|
| Price/Cash flow per share | 4.94 |
| Book value per share | 8.06 |
|---|---|
| Tangible book value per share | 7.97 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.04 |
|---|---|
| Quick ratio | 1.72 |
| Total debt/total equity | 0.1816 |
|---|---|
| Total debt/total capital | 0.1532 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 114.72% and 71.11%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is above the industry average.
| Div yield(5 year avg) | 3.64% |
|---|---|
| Div growth rate (5 year) | 46.04% |
| Payout ratio (TTM) | 34.99% |
| EPS growth(5 years) | 35.74 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 30.07 |
More ▼
